2025-04-25 - Analysis Report
## Teladoc Health Inc (TDOC) Stock Review

**0. Summary of Key Figures:**

* **Cumulative Return (TDOC):** -69.29%
* **Cumulative Return (VOO/S&P 500):** 77.84%
* **Return Difference (TDOC vs VOO):** -147.1% (Relative divergence of 3.9%)
* **Current Price:** $7.26
* **5-Day Moving Average:** $6.91
* **20-Day Moving Average:** $7.38
* **60-Day Moving Average:** $9.41
* **RSI:** 45.82
* **PPO:** 0.66
* **Market Risk Indicator (MRI):** 0.4053 (Medium Risk)
* **Expected Return (Long-term, vs S&P 500):**  -2278.2% (This indicates a significant underperformance expectation relative to the S&P 500 over the long term.)


**1. Company Overview and Performance Comparison:**

Teladoc Health Inc. provides virtual healthcare services.  The stock has significantly underperformed the S&P 500, showing a cumulative return of -69.29% compared to the S&P 500's 77.84% cumulative return.  This represents a substantial difference of -147.1%.  The relative divergence of 3.9% suggests that TDOC's performance is significantly below the S&P 500, falling within the lower range of its historical performance relative to the market index.

The provided alpha and beta analysis shows high volatility and significant negative returns in recent years (-83% to -488% CAGR from 2019-2023), despite relatively high CAGR in prior years.  The high beta values (6.1 to 14.7 in earlier years) indicates substantial price sensitivity to market movements, though this has decreased to below 1 recently, implying that the stock has become comparatively less volatile relative to the overall market.

**2. Recent Price Movement:**

The current price is slightly below the 20-day moving average, suggesting potential short-term downward pressure.  However, it sits significantly below the 60-day moving average, indicating a longer-term downtrend. The recent price change shows a slight upward move (2.69%), which might be a temporary fluctuation.  Further monitoring is needed to ascertain any significant trend reversal.

**3. Technical Indicators and Expected Return:**

The RSI of 45.82 is nearing oversold territory (below 30), potentially suggesting a buying opportunity for some investors, but this should be considered within the overall negative trend.  The PPO of 0.66 indicates that the stock's price momentum is relatively strong compared to its longer-term average. This may not have much meaningful value at this point.

The negative relative divergence (-0.8) points towards a recent short-term decline. The significant negative expected return (-2278.2%) highlights a substantial underperformance prediction relative to the S&P 500 over a longer-term period (2+ years).  The MRI value indicates medium risk.

**4. Recent Earnings Analysis:**

The recent earnings data shows consistent negative EPS figures, indicating ongoing losses.  Revenue remains relatively stable around $0.64B - $0.66B, but the substantial losses raise significant concerns about the company's profitability and sustainability.


| Date       | EPS    | Revenue     |
|------------|--------|-------------|
| 2024-10-31 | -0.19  | $0.64 B     |
| 2024-08-01 | -4.92  | $0.64 B     |
| 2024-04-26 | -0.49  | $0.65 B     |
| 2023-10-27 | -0.35  | $0.66 B     |
| 2024-10-31 | -0.35  | $0.66 B     |


**5. Financial Information:**

The financial data shows relatively stable revenue but alarmingly negative Return on Equity (ROE).  While profit margins appear healthy (70-72%), the consistently negative ROE, indicating the company is not generating returns on its equity, is a major red flag and suggests significant underlying financial issues.

| Quarter    | Revenue  | Profit Margin | Equity    | ROE       |
|------------|----------|---------------|-----------|-----------|
| 2024-12-31 | $0.64B   | 70.50%        | $1.49B    | -3.25%    |
| 2024-09-30 | $0.64B   | 71.94%        | $1.51B    | -2.21%    |
| 2024-06-30 | $0.64B   | 70.73%        | $1.50B    | -55.77%   |
| 2024-03-31 | $0.65B   | 69.89%        | $2.29B    | -3.58%    |
| 2023-12-31 | $0.66B   | 70.72%        | $2.33B    | -1.24%    |


**6. Overall Analysis:**

TDOC's performance is deeply concerning. While the revenue remains relatively stable, the persistent negative EPS, significantly negative ROE, and substantial underperformance against the S&P 500 paint a bleak picture.  The high negative expected return reinforces the significant risk involved in investing in TDOC, especially for long-term investors.  While short-term technical indicators might suggest some potential upward movements, the fundamental issues need to be addressed before considering any investment.  Given the current financial situation and market outlook, a strong cautionary approach is recommended.  Further detailed due diligence, including a thorough analysis of the company's restructuring plans (if any) and future growth prospects, is absolutely crucial before any investment decision.
